The DOI matches its Crossref record; 103 of the 103 references it cites were found in a registry or an index.
Anandamide and vanilloid TRPV1 receptors
Open accessAbstract
A large body of evidence now exists to substantiate that the endocannabinoid, anandamide, activates TRPV1 receptors. It is a low intrinsic efficacy TRPV1 agonist that behaves as a partial agonist in tissues with a low receptor reserve, while in tissues with high receptor reserve and in circumstances associated with certain disease states, it behaves as a full agonist. The efficacy of anandamide as a TRPV1 agonist is influenced by a succession of factors including receptor reserve, phosphorylation, metabolism and uptake, CB 1 receptor activation, voltage, temperature, pH and bovine serum albumin. There are indications that the endocannabinoid system may play a role in the modulation of TRPV1 receptor activation. The activation of TRPV1 receptors by anandamide has potential implications in the treatment of inflammatory, respiratory and cardiovascular disorders. The relative importance of anandamide as a physiological and/or pathophysiological TRPV1 receptor agonist in comparison to other potential candidates has yet to be revealed. British Journal of Pharmacology (2003) 140, 790–801. doi:10.1038/sj.bjp.0705467
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Ahluwalia, J., Yaqoob, M., Urbán, L., Bevan, S., & Nagy, I. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01550.x · Cited by 85
RetractedVanilloid receptors on sensory nerves mediate the vasodilator action of anandamide
Zygmunt, P. M., Petersson, J., Andersson, D. A., Chuang, H.-H., Sørgård, M., Di Marzo, V., Julius, D., & Högestätt, E. D. (1999) · Nature · doi:10.1038/22761 · Cited by 2,142 · cited 6×
“%) a Reference HEK 293(rat) Inward current 7.4 5.3170.06 B30–50 Zygmunt et al. (1999) [Ca2+]i (FLIPR) 7.4 5.7370.04 100 Ralevic et al. (2001) 6.4 5.7670.04 F Ralevic et al. (2001) [Ca2+]i (FLIPR) F 5.8570.01 100 Jerman et al. (2002) [Ca2+]i (Fura-2) F 5.8570.12 (221C) 63 Sprague et al.…”
BackgroundMethodInfluentialFormation and inactivation of endogenous cannabinoid anandamide in central neurons
Di Marzo, V., Fontana, A., Cadas, H., Schinelli, S., Cimino, G., Schwartz, J.-C., & Piomelli, D. (1994) · Nature · doi:10.1038/372686a0 · Cited by 1,587
Protein kinase C activation and the development of diabetic complications.
Koya, D., & King, G. L. (1998) · Diabetes · doi:10.2337/diabetes.47.6.859 · Cited by 1,330
Cravatt, B. F., Demarest, K., Patricelli, M. P., Bracey, M. H., Giang, D. K., Martin, B. R., & Lichtman, A. H. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.161191698 · Cited by 1,310
Chuang, H.-H., Prescott, E. D., Kong, H., Shields, S., Jordt, S.-E., Basbaum, A. I., Chao, M. V., & Julius, D. (2001) · Nature · doi:10.1038/35082088 · Cited by 1,258
Hwang, S. W., Cho, H., Kwak, J., Lee, S.-Y., Kang, C.-J., Jung, J., Cho, S., Min, K. H., Suh, Y.-G., Kim, D., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.11.6155 · Cited by 1,048
Huang, S. M., Bisogno, T., Trevisani, M., Al-Hayani, A., De Petrocellis, L., Fezza, F., Tognetto, M., Petros, T. J., Krey, J. F., Chu, C. J., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.122196999 · Cited by 964
Molecular Basis for Species-Specific Sensitivity to “Hot” Chili Peppers
Jordt, S.-E., & Julius, D. (2002) · Cell · doi:10.1016/s0092-8674(02)00637-2 · Cited by 880
Mezey, É., Tóth, Z. E., Cortright, D. N., Arzubi, M. K., Krause, J. E., Elde, R., Guo, A., Blumberg, P. M., & Szallasi, A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.7.3655 · Cited by 850 · cited 1×
“TRPV1 receptors have been thought to be primarily associated with the peripheral nervous system and in particular, primary afferent fibres, yet PCR studies show that TRPV1 mRNA is present in brain tissue and is especially high in the CA1 and CA3 regions of the hippocampus (Mezey et al., 2000).”
Background
Cited by
Mustard oils and cannabinoids excite sensory nerve fibres through the TRP channel ANKTM1
Jordt, S.-E., Bautista, D. M., Chuang, H.-H., McKemy, D. D., Zygmunt, P. M., Högestätt, E. D., Meng, I. D., & Julius, D. (2004) · Nature · doi:10.1038/nature02282 · Cited by 1,899
AN INTRODUCTION TO TRP CHANNELS
Ramsey, I. S., Delling, M., & Clapham, D. E. (2006) · Annual Review of Physiology · doi:10.1146/annurev.physiol.68.040204.100431 · Cited by 1,551
Cannabinoid pharmacology: the first 66 years
Pertwee, R. G. (2006) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706406 · Cited by 782
Pharmacological Actions of Cannabinoids
Pertwee, R. G. (2005) · Handbook of Experimental Pharmacology · doi:10.1007/3-540-26573-2_1 · Cited by 597
Cristino, L., de Petrocellis, L., Pryce, G., Baker, D., Guglielmotti, V., & Di Marzo, V. (2006) · Neuroscience · doi:10.1016/j.neuroscience.2006.02.074 · Cited by 491
The Endocannabinoid System and Pain
Guindon, J., & Hohmann, A. (2009) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152709789824660 · Cited by 476
Ligresti, A., De Petrocellis, L., & Di Marzo, V. (2016) · Physiological Reviews · doi:10.1152/physrev.00002.2016 · Cited by 469
Allosteric Modulation of the Cannabinoid CB1 Receptor
Price, M. R., Baillie, G. L., Thomas, A., Stevenson, L. A., Easson, M., Goodwin, R., McLean, A., McIntosh, L., Goodwin, G., Walker, G., et al. (2005) · Molecular Pharmacology · doi:10.1124/mol.105.016162 · Cited by 443
Self-citationXu, H., Blair, N. T., & Clapham, D. E. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.2574-05.2005 · Cited by 420
Cannabinoids and the gut: New developments and emerging concepts
Izzo, A. A., & Sharkey, K. A. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.12.005 · Cited by 419
Cabral, G. A., & Griffin-Thomas, L. (2009) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399409000957 · Cited by 408
Endovanilloids: Putative endogenous ligands of transient receptor potential vanilloid 1 channels
van der Stelt, M., & Di Marzo, V. (2004) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.2004.04081.x · Cited by 389
Biochemistry and pharmacology of endovanilloids
Starowicz, K., Nigam, S., & Di Marzo, V. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.01.005 · Cited by 383
Cannabinoids and Pain: New Insights From Old Molecules
Vučković, S., Srebro, D., Vujović, K. S., Vučetić, Č., & Prostran, M. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01259 · Cited by 376
Endocannabinoids–at the crossroads between the gut microbiota and host metabolism
Cani, P. D., Plovier, H., Van Hul, M., Geurts, L., Delzenne, N. M., Druart, C., & Everard, A. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.211 · Cited by 367
The Endocannabinoid System: Drug Targets, Lead Compounds, and Potential Therapeutic Applications
Lambert, D. M., & Fowler, C. J. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm058183t · Cited by 350
Chávez, A. E., Chiu, C. Q., & Castillo, P. E. (2010) · Nature Neuroscience · doi:10.1038/nn.2684 · Cited by 350
The Pharmacology of l-DOPA-Induced Dyskinesia in Parkinson’s Disease
Huot, P., Johnston, T. H., Koprich, J. B., Fox, S. H., & Brotchie, J. M. (2013) · Pharmacological Reviews · doi:10.1124/pr.111.005678 · Cited by 324
The Endocannabinoid System: A Potential Target for the Treatment of Various Diseases
Lowe, H., Toyang, N., Steele, B., Bryant, J., & Ngwa, W. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179472 · Cited by 303
Programming of neural cells by (endo)cannabinoids: from physiological rules to emerging therapies
Maccarrone, M., Guzmán, M., Mackie, K., Doherty, P., & Harkany, T. (2014) · Nature Reviews Neuroscience · doi:10.1038/nrn3846 · Cited by 298
The thermo‐TRP ion channel family: properties and therapeutic implications
Vay, L., Gu, C., & McNaughton, P. A. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01601.x · Cited by 296
A new ESI-LC/MS approach for comprehensive metabolic profiling of phytocannabinoids in Cannabis
Berman, P., Futoran, K., Lewitus, G. M., Mukha, D., Benami, M., Shlomi, T., & Meiri, D. (2018) · Scientific Reports · doi:10.1038/s41598-018-32651-4 · Cited by 292
Role in Anxiety Behavior of the Endocannabinoid System in the Prefrontal Cortex
Rubino, T., Realini, N., Castiglioni, C., Guidali, C., Vigano, D., Marras, E., Petrosino, S., Perletti, G., Maccarrone, M., Di Marzo, V., et al. (2008) · Cerebral Cortex · doi:10.1093/cercor/bhm161 · Cited by 283
Di, S., Malcher-Lopes, R., Marcheselli, V. L., Bazan, N. G., & Tasker, J. G. (2005) · Endocrinology · doi:10.1210/en.2005-0610 · Cited by 282
Moreira, F. A., Kaiser, N., Monory, K., & Lutz, B. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.07.005 · Cited by 281
Expression of Cannabinoid CB1 Receptors by Vagal Afferent Neurons Is Inhibited by Cholecystokinin
Burdyga, G., Lal, S., Varro, A., Dimaline, R., Thompson, D. G., & Dockray, G. J. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.5404-03.2004 · Cited by 280
Recent Developments in Vascular Endothelial Cell Transient Receptor Potential Channels
Yao, X., & Garland, C. J. (2005) · Circulation Research · doi:10.1161/01.res.0000187473.85419.3e · Cited by 275
Supply and demand for endocannabinoids
Alger, B. E., & Kim, J. (2011) · Trends in Neurosciences · doi:10.1016/j.tins.2011.03.003 · Cited by 268
The cannabinoid system and pain
Woodhams, S. G., Chapman, V., Finn, D. P., Hohmann, A. G., & Neugebauer, V. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.06.015 · Cited by 267
The transient receptor potential vanilloid-1 channel in thermoregulation: a thermosensor it is not
Romanovsky, A. A., Almeida, M. C., Garami, A., Steiner, A. A., Norman, M. H., Morrison, S. F., Nakamura, K., Burmeister, J. J., & Nucci, T. B. (2009) · Pharmacological Reviews · doi:10.1124/pr.109.001263 · Cited by 253
Gorzalka, B. B., Hill, M. N., & Hillard, C. J. (2008) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2008.03.004 · Cited by 211
“In addition to these known targets for cannabinoid agents, there is also increasing, but not definitive, evidence that cannabinoids may also exhibit affinity for other receptor subtypes, such as vanilloid receptors (TRPV1; Ross, 2003), peroxisome-proliferator-activated receptors (PPARs; Sun et al.”
BackgroundJuszczak, G. R., & Swiergiel, A. H. (2009) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2008.12.014 · Cited by 211
Bradshaw, H. B., Rimmerman, N., Krey, J. F., & Walker, J. M. (2006) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00933.2005 · Cited by 202
Re, G., Barbero, R., Miolo, A., & Di Marzo, V. (2007) · The Veterinary Journal · doi:10.1016/j.tvjl.2005.10.003 · Cited by 199
Cyclooxygenase-2 in synaptic signaling
Yang, H., & Chen, C. (2008) · Current Pharmaceutical Design · doi:10.2174/138161208784480144 · Cited by 195
Goods and Bads of the Endocannabinoid System as a Therapeutic Target: Lessons Learned after 30 Years
Maccarrone, M., Di Marzo, V., Gertsch, J., Grether, U., Howlett, A. C., Hua, T., Makriyannis, A., Piomelli, D., Ueda, N., & van der Stelt, M. (2023) · Pharmacological Reviews · doi:10.1124/pharmrev.122.000600 · Cited by 183
Moreira, F. A., & Wotjak, C. T. (2009) · Current topics in behavioral neurosciences · doi:10.1007/7854_2009_16 · Cited by 177
Polymodal activation of the endocannabinoid system in the extended amygdala
Puente, N., Cui, Y., Lassalle, O., Lafourcade, M., Georges, F., Venance, L., Grandes, P., & Manzoni, O. J. (2011) · Nature Neuroscience · doi:10.1038/nn.2974 · Cited by 173
Patricio, F., Morales-Andrade, A. A., Patricio-Martínez, A., & Limón, I. D. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.595635 · Cited by 129
Plasma endocannabinoid levels in multiple sclerosis
Jean-Gilles, L., Feng, S., Tench, C. R., Chapman, V., Kendall, D. A., Barrett, D. A., & Constantinescu, C. S. (2009) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2009.07.021 · Cited by 100
Matias, I., Wang, J. W., Moriello, A. S., Nieves, A., Woodward, D. F., & Di Marzo, V. (2006) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2006.08.002 · Cited by 89
Alger, B. E. (2012) · The Journal of Physiology · doi:10.1113/jphysiol.2011.220855 · Cited by 82
Cassano, T., Gaetani, S., Macheda, T., Laconca, L., Romano, A., Morgese, M. G., Cimmino, C. S., Chiarotti, F., Bambico, F. R., Gobbi, G., et al. (2011) · Psychopharmacology · doi:10.1007/s00213-010-2051-0 · Cited by 72
“The α subunit of the Gi protein coupled to CB1 receptor inhibits adenyl cyclase activity, resulting in the inhibition of protein kinase A (PKA) activation, which, in turn, is required for TRPV1 phosphorylation (for review, see Ross 2003 ).”
Cyclooxygenase-2 inhibition reduces stress-induced affective pathology
Gamble-George, J. C., Baldi, R., Halladay, L., Kocharian, A., Hartley, N., Silva, C. G., Roberts, H., Haymer, A., Marnett, L. J., Holmes, A., et al. (2016) · eLife · doi:10.7554/elife.14137 · Cited by 55
Efendiev, R., Bavencoffe, A., Hu, H., Zhu, M. X., & Dessauer, C. W. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.428144 · Cited by 49
Rodella, L. F., Borsani, E., Rezzani, R., Ricci, F., Buffoli, B., & Bianchi, R. (2005) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.12.031 · Cited by 32
Sauer, S. K., & Reeh, P. W. (2009) · Digestive Diseases · doi:10.1159/000268116 · Cited by 9
Metadata
- Authors
- Ross, R. A.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2003-11
- Volume
- 140
- Issue
- 5
- Pages
- 790-801
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W2057468498
- Cited by
- 604
- References
- 103
- FWCI
- 9.50
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.